Equities analysts expect that Rubius Therapeutics Inc (NASDAQ:RUBY) will report earnings of ($0.36) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Rubius Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.27). The business is scheduled to report its next earnings results on Friday, November 30th.
On average, analysts expect that Rubius Therapeutics will report full year earnings of ($1.70) per share for the current year, with EPS estimates ranging from ($2.61) to ($1.03). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.50) per share, with EPS estimates ranging from ($1.90) to ($0.99). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Rubius Therapeutics.
Rubius Therapeutics (NASDAQ:RUBY) last released its quarterly earnings results on Friday, August 31st. The company reported ($3.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($2.73). During the same quarter in the prior year, the company posted ($1.25) earnings per share.
Several research firms recently weighed in on RUBY. Leerink Swann began coverage on Rubius Therapeutics in a research report on Monday, August 13th. They set an “outperform” rating on the stock. Morgan Stanley began coverage on Rubius Therapeutics in a research report on Monday, August 13th. They set an “overweight” rating and a $37.00 price target on the stock. JPMorgan Chase & Co. began coverage on Rubius Therapeutics in a research report on Monday, August 13th. They set an “overweight” rating on the stock. Finally, Jefferies Financial Group began coverage on Rubius Therapeutics in a research report on Monday, August 13th. They set a “buy” rating and a $40.00 price target on the stock.
In other news, Director Francis M. Cuss purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, July 20th. The shares were bought at an average cost of $23.00 per share, for a total transaction of $230,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ RUBY opened at $17.96 on Wednesday. The company has a current ratio of 12.27, a quick ratio of 12.27 and a debt-to-equity ratio of -0.28. Rubius Therapeutics has a twelve month low of $17.93 and a twelve month high of $33.01.
Rubius Therapeutics Company Profile
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.